Search Clinical Trials
Sponsor Condition of Interest |
---|
An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With...
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
This is a multicenter, prospective, observational Phase 4 study in the United States. The
study is designed to collect both medical history and prospective data on Duchenne
muscular dystrophy (DMD) treatment outcomes in participants receiving delandistrogene
moxeparvovec as part of clinical care,... expand
This is a multicenter, prospective, observational Phase 4 study in the United States. The study is designed to collect both medical history and prospective data on Duchenne muscular dystrophy (DMD) treatment outcomes in participants receiving delandistrogene moxeparvovec as part of clinical care, compared to participants with DMD receiving or prescribed to start chronic glucocorticoid treatment at baseline in routine clinical practice. In addition, treatment outcomes will be collected prospectively from post-trial participants who have received delandistrogene moxeparvovec through participation in select SRP-9001 studies. Type: Observational Start Date: Feb 2024 |
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
National Cancer Institute (NCI)
Stage II Nasopharyngeal Carcinoma AJCC v8
Stage III Nasopharyngeal Carcinoma AJCC v8
Stage IV Nasopharyngeal Carcinoma AJCC v8
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs
prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy
with monoclonal antibodies, such as nivolumab, may help the body's immune system attack
the cancer, and may interfere with the... expand
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy. Type: Interventional Start Date: Jun 2024 |
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
Adamantinous Craniopharyngioma
Recurrent Adamantinomatous Craniopharyngioma
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of
mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological
activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide
variety of tumor types In this Phase II, the drug... expand
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy. Type: Interventional Start Date: Apr 2023 |
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma
University of California, San Francisco
Medulloblastoma
Medulloblastoma, Childhood
Medulloblastoma Recurrent
The current study will use a new treatment approach based on the molecular
characteristics of each participant's tumor. The study will test the feasibility of
performing real-time drug screening on tissue taken during surgery, and of having a
specialized tumor board assign a treatment plan based on... expand
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with medulloblastoma to receive the most effective and least toxic therapies currently available, and will pave the way for improved understanding and treatment of these tumors in the future. Type: Interventional Start Date: Feb 2022 |
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Nationwide Children's Hospital
High Grade Glioma
Diffuse Intrinsic Pontine Glioma
This is a pilot study that will evaluate disease status in children that have been newly
diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of
the medication (Larotrectinib) have been given.
The study will also evaluate the safety of larotrectinib when given with... expand
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy. Type: Interventional Start Date: Apr 2021 |
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
Catherine Bollard
Viral Infection
This Phase I-II dose-finding trial to determine the optimal dose of intravenous (IV)
injection dose of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV
and Adenovirus. A maximum of 36 patients will be treated in up to 18 cohorts each of size
2, with the first cohort treated... expand
This Phase I-II dose-finding trial to determine the optimal dose of intravenous (IV) injection dose of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV and Adenovirus. A maximum of 36 patients will be treated in up to 18 cohorts each of size 2, with the first cohort treated at the lowest dose level 1, all successive doses chosen by the EffTox method, and no untried dose level skipped when escalating. The scientific goal of the trial is to determine an optimal IV-CTL cell dose level among the three doses 1.0x107cells/m2, 2 x107cells/m2 and 5x107cells/m2., hereafter dose levels 1, 2, 3. Dose-finding will be done using the sequentially adaptive EffTox trade-off-based design of Thall et al. Type: Interventional Start Date: Jan 2018 |
Childhood Cancer Survivor Study
St. Jude Children's Research Hospital
Cancer
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of
cancer and its associated therapies. A retrospective cohort study will be conducted
through a multi-institutional collaboration, which will involve the identification and
active follow-up of a cohort of approximately... expand
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, who are at increased risk of late-occurring adverse health outcomes. A group of sibling controls will be identified and data collected for comparison purposes. Type: Observational Start Date: Jan 1995 |
Study of Kidney Tumors in Younger Patients
Children's Oncology Group
Adult Cystic Nephroma
Anaplastic Kidney Wilms Tumor
Angiolipoma
Cellular Congenital Mesoblastic Nephroma
Classic Congenital Mesoblastic Nephroma
This research trial studies kidney tumors in younger patients. Collecting and storing
samples of tumor tissue, blood, and urine from patients with cancer to study in the
laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid
(DNA) and identify biomarkers related to... expand
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. Type: Observational Start Date: Feb 2006 |
Measuring Analgesic Interventions
Julia Finkel
Pain
It is generally recognized that pain assessment and management especially in newborns,
children and other nonverbal populations is an unmet need. According to the American
Medical Association, "the pediatric population is at risk of inadequate pain management,
with age-related factors affecting pain... expand
It is generally recognized that pain assessment and management especially in newborns, children and other nonverbal populations is an unmet need. According to the American Medical Association, "the pediatric population is at risk of inadequate pain management, with age-related factors affecting pain management in children. Children are often given minimal or no analgesia for procedures that would routinely be treated aggressively in adults. Although much is now known about pain management in children, it has not been widely or effectively translated into routine clinical practice". These two factors combine to emphasize the necessity for an objective tool to quantify pain and monitor the effectiveness of analgesia, especially during treatments. Further, it is reported that many patients require a combination of treatments, and it is often necessary to test a variety of treatments before the personal match for treatment is found. The method in place to change the care on a subjective basis is difficult, time consuming, and not easily individualized. This pilot study is part of an ongoing effort to develop a method to objectively assess response to specific analgesic interventions. It specifically aims to discern the impact of analgesic interventions on sensory nerve fiber sensitivity in a diverse patient population. Type: Observational Start Date: Oct 2018 |
Individualized Nutrition to Optimize Preterm Infant Growth and Neurodevelopment
Children's National Research Institute
Very Preterm Maturity of Infant
Very Low Birth Weight Infant
Human milk has several well-established benefits but does not adequately meet the
increased nutritional demands of the growing preterm infant, necessitating additional
nutrient supplementation in a process known as fortification. In U.S. neonatal intensive
care units (NICUs), human milk is primarily... expand
Human milk has several well-established benefits but does not adequately meet the increased nutritional demands of the growing preterm infant, necessitating additional nutrient supplementation in a process known as fortification. In U.S. neonatal intensive care units (NICUs), human milk is primarily supplemented using standardized fortification, in which a multicomponent fortifier is added to human milk to achieve assumed nutrient content based on standard milk reference values. However, this method does not account for the significant variability in human milk composition or in preterm infant metabolism, and up to half of all very premature infants experience poor growth and malnutrition using current nutritional practices. Poor postnatal growth has adverse implications for the developing preterm brain and long-term neurodevelopment. Recent advances allow for individualized methods of human milk fortification, including adjustable and targeted fortification. Adjustable fortification uses laboratory markers of protein metabolism (BUN level) to estimate an infant's protein requirements. In targeted fortification, a milk sample is analyzed to determine its specific macronutrient and energy content, with additional macronutrient supplementation provided as needed to achieve goal values. Emerging data suggest that both methods are safe and effective for improving growth, however information on their comparable efficacy and neurodevelopmental implications are lacking, particularly using advanced quantitative brain MRI (qMRI) techniques. Through this prospective, randomized-controlled trial, the investigators will compare the impact of individualized human milk fortification on somatic growth and neurodevelopment in preterm infants. Infants will be randomized to receive one of three nutritional interventions: standardized (control group), adjustable, or targeted human milk fortification. Infants will undergo their assigned nutritional intervention until term-equivalent age or discharge home, whichever is achieved first. Brain qMRI will be performed at term-corrected age, and neurodevelopmental follow-up will be performed through 5 years of age. Type: Interventional Start Date: Feb 2024 |
T CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS
Children's National Research Institute
SARS-CoV-2 Infection
This is an open label, phase I dose-escalation study to evaluate the safety of
coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in
immunocompromised patients following hematopoietic stem cell transplantation (HSCT).
Participants will receive donor-derived CSTs for... expand
This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and <4 months after HSCT). In this dose escalation trial, three doses (1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and <80 years) HSCT recipients (Arm A) and pediatric (≥12 years of age and <18 years) HSCT recipients (Arm B), and defined dose escalations in each study arm. The study agent will be assessed for safety (stopping rules defined) and antiviral activity. Type: Interventional Start Date: Oct 2021 |
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of California, San Francisco
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent WHO Grade III Glioma
This phase II trial determines if the combination of ONC201 with different drugs,
panobinostat or paxalisib, is effective for treating participants with diffuse midline
gliomas (DMGs). Despite years of research, little to no progress has been made to improve
outcomes for participants with DMGs, and... expand
This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. ONC201, panobinostat, and paxalisib are all enzyme inhibitors that may stop the growth of tumor cells by clocking some of the enzymes needed for cell growth. This phase II trial assesses different combinations of these drugs for the treatment of DMGs. Type: Interventional Start Date: Oct 2021 |
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal...
National Cancer Institute (NCI)
Primary Mediastinal Large B-Cell Lymphoma
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus
chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal
B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may
help the body's immune system attack... expand
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL. Type: Interventional Start Date: Oct 2021 |
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
The Hospital for Sick Children
Heart Block Complete
Heart Block Second Degree
Few studies are specifically designed to address health concerns that are already
relevant during pregnancy. The consequence is a lack of evidence on best clinical
practice. This includes mothers and their babies when pregnancy is complicated by an
abnormally slow heart rate due to maternal antibody-mediated... expand
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharmaceuticals administered via the mother. To this day, physicians need to make decisions about the management of such pregnancies without evidence from prospective clinical trials on drug efficacy and safety. The SLOW HEART REGISTRY is a multi-centered prospective observational study that will address the knowledge gap to guide future management of high-degree immune-mediated heart block to the best of care. The study seeks to establish an international database of the management and outcome of affected fetuses, to be used to publish information on the results of currently available prenatal care and to evaluate the need for additional research. Type: Observational [Patient Registry] Start Date: Jan 2020 |
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
Children's Hospital Medical Center, Cincinnati
Hypoplastic Left Heart Syndrome (HLHS)
The purpose of this initiative is to improve care and outcomes for infants with HLHS by
expanding the NPC-QIC national registry to gather clinical care process, outcome, and
developmental data on infants with HLHS between diagnosis and 12 months of age, by
improving the use of standards into everyday... expand
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process. Type: Observational [Patient Registry] Start Date: May 2016 |
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and...
Michael Shy
Charcot Marie Tooth Disease
This is an observational longitudinal study to determine the natural history and
genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth
disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).
The investigators will also be determine the capability of the... expand
This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window Type: Observational Start Date: Apr 2010 |
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Kiniksa Pharmaceuticals (UK), Ltd.
Recurrent Pericarditis
The registry will focus on furthering the understanding of the natural history of
recurrent pericarditis (RP), as well as document RP-related clinical, health-related
quality of life (HRQoL), and economic burden and will assist the medical community to
refine or develop data-driven recommendations... expand
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population. Type: Observational [Patient Registry] Start Date: Mar 2021 |
Pediatric Percutaneous Ultrasound Gastrostomy Technique
CoapTech
Gastrostomy
Gastrostomy Complications
Pediatric Disorder
Ultrasound
The purpose of this research study is to test a new device called the PUMA-G Pediatric
System. The research will measure if the device works well to safely aid doctors placing
gastrostomy feeding tubes in children. The PUMA-G Pediatric System is an investigational
device that uses ultrasound and magnets... expand
The purpose of this research study is to test a new device called the PUMA-G Pediatric System. The research will measure if the device works well to safely aid doctors placing gastrostomy feeding tubes in children. The PUMA-G Pediatric System is an investigational device that uses ultrasound and magnets to guide insertion of a feeding tube. Type: Interventional Start Date: Jul 2023 |
International Rare Brain Tumor Registry
Children's National Research Institute
Astroblastoma
BCOR ITD Sarcoma
CNS Sarcoma
Unclassified Tumor, Malignant
The objective of the International Rare Brain Tumor Registry (IRBTR) is to better
understand rare brain tumors through the collection of biospecimens and matched clinical
data of children, adolescents, and young adult patients diagnosed with rare brain tumors. expand
The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed with rare brain tumors. Type: Observational [Patient Registry] Start Date: Jan 2023 |
Orphan Europe Carbaglu® Surveillance Protocol
Nicholas Ah Mew
N-acetylglutamate Synthase (NAGS) Deficiency
The purpose of this study is to conduct post-marketing surveillance of carglumic acid
(Carbaglu) to obtain long-term clinical safety information. Carglumic acid was approved
by the United States Food and Drug Administration (FDA) for treatment of acute
hyperammonemia due to N-acetylglutamate synthase... expand
The purpose of this study is to conduct post-marketing surveillance of carglumic acid (Carbaglu) to obtain long-term clinical safety information. Carglumic acid was approved by the United States Food and Drug Administration (FDA) for treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Much of the FDA-required data is already collected through the Longitudinal Study of Urea Cycle Disorders (RDCRN Protocol #5101). This study will collect additional data on adverse events (interim events), adverse reactions, pregnancy, and fetal outcomes. Type: Observational [Patient Registry] Start Date: Apr 2012 |
The Myelin Disorders Biorepository Project
Children's Hospital of Philadelphia
Leukodystrophy
White Matter Disease
Leukoencephalopathies
4H Syndrome
Adrenoleukodystrophy
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical
data and biological samples from leukodystrophy patients worldwide to support ongoing and
future research projects. The MDBP is one of the world's largest leukodystrophy
biorepositories, having enrolled nearly... expand
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future. Type: Observational [Patient Registry] Start Date: Dec 2016 |
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
University of Alabama at Birmingham
Respiratory Syncytial Virus Infections
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM)
during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be
beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway. expand
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway. Type: Interventional Start Date: Feb 2022 |
A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult...
InSightec
Benign Centrally-Located Intracranial Tumors
The goal of this prospective, non-randomized, single-arm, feasibility study is to develop
data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign
intracranial tumors which require clinical intervention in pediatric and young adult
subjects.
Indication of Use: Ablation of... expand
The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible. Type: Interventional Start Date: Feb 2017 |
The Pediatric Anesthesia Quality Improvement Project
The Society for Pediatric Anesthesia
Surgery
Anesthesia
Children
The Study is designed to collect information about adverse events that occur in children
undergoing anesthesia in participating hospitals. Demographic information will be
collected on all anesthetics. An analysis of each adverse event will be performed and
entered into the database. From this information... expand
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events. Type: Observational [Patient Registry] Start Date: Feb 2008 |
Evaluation of The Food Allergy Mastery Program
Children's National Research Institute
Food Allergy in Children
The proposed research project will evaluate a novel behavioral intervention that promotes
early adolescent food allergy self-management and adjustment through 1) food allergy
education, 2) problem-solving, communication, assertiveness, and anxiety management skill
building, and 3) peer support. expand
The proposed research project will evaluate a novel behavioral intervention that promotes early adolescent food allergy self-management and adjustment through 1) food allergy education, 2) problem-solving, communication, assertiveness, and anxiety management skill building, and 3) peer support. Type: Interventional Start Date: Jun 2023 |
- Previous
- Next